Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Panel Recommends Japan Continue Ban On Tamiflu For Teenagers

This article was originally published in PharmAsia News

Executive Summary

Japan is keeping in place for now its ban on the use of Roche's Tamiflu (oseltamivir) flu drug for teenagers. A panel convened by the Health, Labor and Welfare Ministry recommended the ban be kept in place after reviewing a survey on the risk of abnormal behavior by teens who took the drug. Researchers are calling for more studies to determine the exact cause of the abnormal behavior, some saying it could have been the flu itself and not the drug to treat it that was responsible. The ban on its use in teens took effect just over two years ago, but it also is one of the major treatments for the H1N1 flu now affecting many Japanese. (Click here for more

You may also be interested in...

QUOTED. 20 January 2020. Henrik Berggren.

San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.

China Commits To Patent Linkage And Extensions In US Trade Deal

The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions. 


Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts